O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+6.96%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.91B
AUM Growth
+$7.91B
(+12%)
Cap. Flow
+$959M
Cap. Flow
% of AUM
12.12%
Top 10 Holdings %
Top 10 Hldgs %
33.78%
Holding
159
New
26
Increased
22
Reduced
25
Closed
17
Top Buys
| 1 |
Prelude Therapeutics
PRLD
|
$470M |
| 2 |
PMV Pharmaceuticals
PMVP
|
$260M |
| 3 |
AFIB
Acutus Medical, Inc. Common Stock
AFIB
|
$163M |
| 4 |
CalciMedica
CALC
|
$56.9M |
| 5 |
Theravance Biopharma
TBPH
|
$54.2M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$128M |
| 2 |
Cigna
CI
|
$82.5M |
| 3 |
Natera
NTRA
|
$81.6M |
| 4 |
Glaukos
GKOS
|
$46.5M |
| 5 |
Alector
ALEC
|
$34.2M |
Sector Composition
| 1 | Healthcare | 98.49% |
| 2 | Financials | 0.64% |
| 3 | Technology | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Arcus Biosciences
RCUS
$1.13B
| – | – | -220,350 | Closed | -$5.45M |
|
152
Regeneron Pharmaceuticals
REGN
$61.5B
| – | – | -30,900 | Closed | -$19.3M |
|
153
SelectQuote
SLQT
$391M
| – | – | -1,255,000 | Closed | -$31.8M |
|
154
10x Genomics
TXG
$1.74B
| – | – | -92,700 | Closed | -$8.28M |
|
155
VYNE Therapeutics
VYNE
$8.16M
| – | – | -593,883 | Closed | -$1.03M |
|
|
GNMK
156
DELISTED
GenMark Diagnostics, Inc
GNMK
| – | – | -732,000 | Closed | -$10.8M |
|
|
IMMU
157
DELISTED
Immunomedics Inc
IMMU
| – | – | -757,900 | Closed | -$26.9M |
|
|
BFYT
158
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| – | – | -962,900 | Closed | -$19.7M |
|
159
Arvinas
ARVN
$568M
| – | – | -29,400 | Closed | -$986K |
|